Systems biology approaches and tools for analysis of interactomes and multi-target drugs

Methods in Molecular Biology

Volumn 662, Issue , 2010, Pages 29-58

  Schrattenholz, André ^a   Groebe, Karlfried ^b   Soskic, Vukic ^b  

^a PROTEOSYS AG   (Germany)

^b NONE

Author keywords

Genomics; Interactome; Multi target drugs; Network; Posttranslational modification; Proteomics; Systems biology

Indexed keywords

EID: 84934438895     PISSN: 10643745     EISSN: None     Source Type: Book Series    
DOI: 10.1007/978-1-60761-800-3_2     Document Type: Article

References (123)

1. Boone C, Bussey H, Andrews BJ (2007) Exploring genetic interactions and networks with yeast. Nat Rev Genet 8:437-449
2. Davierwala AP, Haynes J, Li Z, Brost RL, Robinson MD, Yu L, Mnaimneh S, Ding H, Zhu H, Chen Y, Cheng X, Brown GW, Boone C, Andrews BJ, Hughes TR (2005) The synthetic genetic interaction spectrum of essential genes. Nat Genet 37:1147-1152
3. Tong AH, Lesage G, Bader GD, Ding H, Xu H, Xin X, Young J, Berriz GF, Brost RL, Chang M, Chen Y, Cheng X, Chua G, Friesen H, Goldberg DS, Haynes J, Humphries C, He G, Hussein S, Ke L, Krogan N, Li Z, Levinson JN, Lu H, Menard P, Munyana C, Parsons AB, Ryan O, Tonikian R, Roberts T, Sdicu AM, Shapiro J, Sheikh B, Suter B, Wong SL, Zhang LV, Zhu H, Burd CG, Munro S, Sander C, Rine J, Greenblatt J, Peter M, Bretscher A, Bell G, Roth FP, Brown GW, Andrews B, Bussey H, Boone C (2004) Global mapping of the yeast genetic interaction network. Science 303:808-813
4. Hughes TR, Robinson MD, Mitsakakis N, Johnston M (2004) The promise of functional genomics: completing the encyclopedia of a cell. Curr Opin Microbiol 7:546-554
5. Dolinski K, Botstein D (2005) Changing perspectives in yeast research nearly a decade after the genome sequence. Genome Res 15:1611-1619
6. Lehner B, Crombie C, Tischler J, Fortunato A, Fraser AG (2006) Systematic mapping of genetic interactions in Caenorhabditis elegans identifies common modifiers of diverse signaling pathways. Nat Genet 38:896-903
7. Schlabach MR, Luo J, Solimini NL, Hu G, Xu Q, Li MZ, Zhao Z, Smogorzewska A, Sowa ME, Ang XL, Westbrook TF, Liang AC, Chang K, Hackett JA, Harper JW, Hannon GJ, Elledge SJ (2008) Cancer proliferation gene discovery through functional genomics. Science 319:620-624
8. Silva JM, Marran K, Parker JS, Silva J, Golding M, Schlabach MR, Elledge SJ, Hannon GJ, Chang K (2008) Profiling essential genes in human mammary cells by multiplex RNAi screening. Science 319:617-620
9. Berns K, Horlings HM, Hennessy BT, Madiredjo M, Hijmans EM, Beelen K, Linn SC, Gonzalez-Angulo AM, Stemke-Hale K, Hauptmann M, Beijersbergen RL, Mills GB, van de V, Bernards R (2007) A functional genetic approach identifies the PI3K pathway as a major determinant of trastuzumab resistance in breast cancer. Cancer Cell 12:395-402
10. Cordell HJ (2002) Epistasis: what it means, what it doesn't mean, and statistical methods to detect it in humans. Hum Mol Genet 11:2463-2468
11. Luo B, Cheung HW, Subramanian A, Sharifnia T, Okamoto M, Yang X, Hinkle G, Boehm JS, Beroukhim R, Weir BA, Mermel C, Barbie DA, Awad T, Zhou X, Nguyen T, Piqani B, Li C, Golub TR, Meyerson M, Hacohen N, Hahn WC, Lander ES, Sabatini DM, Root DE (2008) Highly parallel identification of essential genes in cancer cells. Proc Natl Acad Sci USA 105:20380-20385
12. Ito T, Chiba T, Ozawa R, Yoshida M, Hattori M, Sakaki Y (2001) A comprehensive twohybrid analysis to explore the yeast protein interactome. Proc Natl Acad Sci USA 98:4569-4574
13. Uetz P, Giot L, Cagney G, Mansfield TA, Judson RS, Knight JR, Lockshon D, Narayan V, Srinivasan M, Pochart P, Qureshi-Emili A, Li Y, Godwin B, Conover D, Kalbfleisch T, Vijayadamodar G, Yang M, Johnston M, Fields S, Rothberg JM (2000) A comprehensiveanalysis of protein-protein interactions in Saccharomyces cerevisiae. Nature 403:623-627
14. Ho Y, Gruhler A, Heilbut A, Bader GD, Moore L, Adams SL, Millar A, Taylor P, Bennett K, Boutilier K, Yang L, Wolting C, Donaldson I, Schandorff S, Shewnarane J, Vo M, Taggart J, Goudreault M, Muskat B, Alfarano C, Dewar D, Lin Z, Michalickova K, Willems AR, Sassi H, Nielsen PA, Rasmussen KJ, Andersen JR, Johansen LE, Hansen LH, Jespersen H, Podtelejnikov A, Nielsen E, Crawford J, Poulsen V, Sorensen BD, Matthiesen J, Hendrickson RC, Gleeson F, Pawson T, Moran MF, Durocher D, Mann M, Hogue CW, Figeys D, Tyers M (2002) Systematic identification of protein complexes in Saccharomyces cerevisiae by mass spectrometry. Nature 415:180-183
15. Krogan NJ, Cagney G, Yu H, Zhong G, Guo X, Ignatchenko A, Li J, Pu S, Datta N, Tikuisis AP, Punna T, Peregrin-Alvarez JM, Shales M, Zhang X, Davey M, Robinson MD, Paccanaro A, Bray JE, Sheung A, Beattie B, Richards DP, Canadien V, Lalev A, Mena F, Wong P, Starostine A, Canete MM, Vlasblom J, Wu S, Orsi C, Collins SR, Chandran S, Haw R, Rilstone JJ, Gandi K, Thompson NJ, Musso G, St OP, Ghanny S, Lam MH, Butland G, Altaf-Ul AM, Kanaya S, Shilatifard A, O'Shea E, Weissman JS, Ingles CJ, Hughes TR, Parkinson J, Gerstein M, Wodak SJ, Emili A, Greenblatt JF (2006) Global landscape of protein complexes in the yeast Saccharomyces cerevisiae. Nature 440:637-643
16. Gavin AC, Bosche M, Krause R, Grandi P, Marzioch M, Bauer A, Schultz J, Rick JM, Michon AM, Cruciat CM, Remor M, Hofert C, Schelder M, Brajenovic M, Ruffner H, Merino A, Klein K, Hudak M, Dickson D, Rudi T, Gnau V, Bauch A, Bastuck S, Huhse B, Leutwein C, Heurtier MA, Copley RR, Edelmann A, Querfurth E, Rybin V, Drewes G, Raida M, Bouwmeester T, Bork P, Seraphin B, Kuster B, Neubauer G, Superti- Furga G (2002) Functional organization of the yeast proteome by systematic analysis of protein complexes. Nature 415:141-147
17. Winzeler EA, Shoemaker DD, Astromoff A, Liang H, Anderson K, Andre B, Bangham R, Benito R, Boeke JD, Bussey H, Chu AM, Connelly C, Davis K, Dietrich F, Dow SW, El BM, Foury F, Friend SH, Gentalen E, Giaever G, Hegemann JH, Jones T, Laub M, Liao H, Liebundguth N, Lockhart DJ, Lucau-Danila A, Lussier M, M'Rabet N, Menard P, Mittmann M, Pai C, Rebischung C, Revuelta JL, Riles L, Roberts CJ, Ross- MacDonald P, Scherens B, Snyder M, Sookhai-Mahadeo S, Storms RK, Veronneau S, Voet M, Volckaert G, Ward TR, Wysocki R, Yen GS, Yu K, Zimmermann K, Philippsen P, Johnston M, Davis RW (1999) Functional characterization of the S. cerevisiae genome by gene deletion and parallel analysis. Science 285:901-906
18. Maxwell CA, Moreno V, Sole X, Gomez L, Hernandez P, Urruticoechea A, Pujana MA (2008) Genetic interactions: the missing links for a better understanding of cancer susceptibility, progression and treatment. Mol Cancer 7:4
19. Groebe K, Krause F, Kunstmann B, Unterluggauer H, Reifschneider NH, Scheckhuber CQ, Sastri C, Stegmann W, Wozny W, Schwall GP, Poznanovic S, Dencher NA, Jansen-Durr P, Osiewacz HD, Schrattenholz A (2007) Differential proteomic profiling of mitochondria from Podospora anserina, rat and human reveals distinct patterns of age-related oxidative changes. Exp Gerontol 42:887-898
20. Parsons AB, Brost RL, Ding H, Li Z, Zhang C, Sheikh B, Brown GW, Kane PM, Hughes TR, Boone C (2004) Integration of chemical- genetic and genetic interaction data links bioactive compounds to cellular target pathways. Nat Biotechnol 22:62-69
21. Sharom JR, Bellows DS, Tyers M (2004) From large networks to small molecules. Curr Opin Chem Biol 8:81-90
22. Burkard ME, Randall CL, Larochelle S, Zhang C, Shokat KM, Fisher RP, Jallepalli PV (2007) Chemical genetics reveals the requirement for Polo-like kinase 1 activity in positioning RhoA and triggering cytokinesis in human cells. Proc Natl Acad Sci USA 104:4383-4388
23. Larochelle S, Merrick KA, Terret ME, Wohlbold L, Barboza NM, Zhang C, Shokat KM, Jallepalli PV, Fisher RP (2007) Requirements for Cdk7 in the assembly of Cdk1/cyclin B and activation of Cdk2 revealed by chemical genetics in human cells. Mol Cell 25:839-850
24. Schrattenholz A, Soskic V (2008) What does systems biology mean for drug development? Curr Top Med Chem 15:1520-1528
25. Ashburn TT, Thor KB (2004) Drug repositioning: identifying and developing new uses for existing drugs. Nat Rev Drug Discov 3:673-683
26. Youdim MB (2007) Magic bullets or novel multimodal drugs with various CNS targets for Parkinson's disease? Nat Rev Drug Discov 6:499-500
27. Natt F (2007) siRNAs in drug discovery: target validation and beyond. Curr Opin Mol Ther 9:242-24728.
28. Burbaum J, Tobal GM (2002) Proteomics in drug discovery. Curr Opin Chem Biol 6:427-433
29. Keskin O, Gursoy A, Ma B, Nussinov R (2007) Towards drugs targeting multiple proteins in a systems biology approach. Curr Top Med Chem 7:943-951
30. Soskic V, Klemm M, Proikas-Cezanne T, Schwall GP, Poznanovic S, Stegmann W, Groebe K, Zengerling H, Schoepf R, Burnet M, Schrattenholz A (2007) A connection between the mitochondrial permeability transition pore, autophagy and cerebral amyloidogenesis. J Proteome Res 7:2262-2269
31. Drews J, Ryser S (1997) The role of innovation in drug development. Nat Biotechnol 15:1318-1319
32. Imming P, Sinning C, Meyer A (2006) Drugs, their targets and the nature and number of drug targets. Nat Rev Drug Discov 5:821-834
33. Schrattenholz A, Soskic V (2006) NMDA receptors are not alone: dynamic regulation of NMDA receptor structure and function by neuregulins and transient cholesterol-rich membrane domains leads to disease-specific nuances of glutamate-signalling. Curr Top Med Chem 6:663-686
34. Apic G, Ignjatovic T, Boyer S, Russell RB (2005) Illuminating drug discovery with biological pathways. FEBS Lett 579:1872-1877
35. Huang S, Ingber DE (2006) A non-genetic basis for cancer progression and metastasis: self-organizing attractors in cell regulatory networks. Breast Dis 26:27-54
36. Tsuda I, Fujii H (2007) Chaos reality in the brain. J Integr Neurosci 6:309-326
37. Schoner G, Scholz JP (2007) Analyzing variance in multi-degree-of-freedom movements: uncovering structure versus extracting correlations. Mot Control 11:259-275
38. Southern J, Pitt-Francis J, Whiteley J, Stokeley D, Kobashi H, Nobes R, Kadooka Y, Gavaghan D (2008) Multi-scale computational modelling in biology and physiology. Prog Biophys Mol Biol 96:60-89
39. Price ND, Shmulevich I (2007) Biochemical and statistical network models for systems biology. Curr Opin Biotechnol 18:365-370
40. Konopka AK (2007) Surrogacy theory and models of convoluted organic systems. Proteomics 7:846-856
41. Huang S, Wikswo J (2006) Dimensions of systems biology. Rev Physiol Biochem Pharmacol 157:81-104
42. Boelsterli UA, Lim PL (2007) Mitochondrial abnormalities - a link to idiosyncratic drug hepatotoxicity? Toxicol Appl Pharmacol 220:92-107
43. Dykens JA, Marroquin LD, Will Y (2007) Strategies to reduce late-stage drug attrition due to mitochondrial toxicity. Expert Rev Mol Diagn 7:161-175
44. Lecellier G, Brenner C (2007) Genomic and proteomic screening of apoptosis mitochondrial regulators for drug target discovery. Curr Med Chem 14:875-881
45. Roses AD, Saunders AM, Huang Y, Strum J, Weisgraber KH, Mahley RW (2007) Complex disease-associated pharmacogenetics: drug efficacy, drug safety, and confirmation of a pathogenetic hypothesis (Alzheimer's disease). Pharmacogenomics J 7:10-28
46. Jonker DM, Visser SA, van der Graaf PH, Voskuyl RA, Danhof M (2005) Towards a mechanism-based analysis of pharmacodynamic drug-drug interactions in vivo. Pharmacol Ther 106:1-18
47. Harman D (1956) Aging: a theory based on free radical and radiation chemistry. J Gerontol 11:298-300
48. Ward M (2007) Biomarkers for Alzheimer's disease. Expert Rev Mol Diagn 7:635-646
49. Filley CM, Rollins YD, Anderson CA, Arciniegas DB, Howard KL, Murrell JR, Boyer PJ, Kleinschmidt-DeMasters BK, Ghetti B (2007) The genetics of very early onset Alzheimer disease. Cogn Behav Neurol 20:149-156
50. Sonnen JA, Keene CD, Montine KS, Li G, Peskind ER, Zhang J, Montine TJ (2007) Biomarkers for Alzheimer's disease. Expert Rev Neurother 7:1021-1028
51. Ertekin-Taner N (2007) Genetics of Alzheimer's disease: a centennial review. Neurol Clin 25:611-667
52. Chai CK (2007) The genetics of Alzheimer's disease. Am J Alzheimers Dis Other Demen 22:37-41
53. Mancuso M, Coppede F, Murri L, Siciliano G (2007) Mitochondrial cascade hypothesis of Alzheimer's disease: myth or reality? Antioxid Redox Signal 9:1631-1646
54. Reid PC, Urano Y, Kodama T, Hamakubo T (2007) Alzheimer's disease: cholesterol, membrane rafts, isoprenoids and statins. J Cell Mol Med 11:383-392
55. Argyle DJ, Blacking T (2008) From viruses to cancer stem cells: dissecting the pathways to malignancy. Vet J 177:311-323
56. Sales KM, Winslet MC, Seifalian AM (2007) Stem cells and cancer: an overview. Stem Cell Rev 3:249-255
57. Alison MR, Murphy G, Leedham S (2008) Stem cells and cancer: a deadly mix. Cell Tissue Res 331:109-124
58. Erenpreisa J, Cragg MS (2007) Cancer: a matter of life cycle? Cell Biol Int 31:1507-1510
59. Sjoblom T, Jones S, Wood LD, Parsons DW, Lin J, Barber TD, Mandelker D, Leary RJ, Ptak J, Silliman N, Szabo S, Buckhaults P, Farrell C, Meeh P, Markowitz SD, Willis J, Dawson D, Willson JK, Gazdar AF, Hartigan J, Wu L, Liu C, Parmigiani G, Park BH, Bachman KE, Papadopoulos N, Vogelstein B, Kinzler KW, Velculescu VE (2006) The consensus coding sequences of human breast and colorectal cancers. Science 314:268-274
60. Venkatesan RN, Bielas JH, Loeb LA (2006) Generation of mutator mutants during carcinogenesis. DNA Repair (Amst) 5:294-302
61. Araujo RP, Liotta LA, Petricoin EF (2007) Proteins, drug targets and the mechanisms they control: the simple truth about complex networks. Nat Rev Drug Discov 6:871-880
62. Lehar J, Zimmermann GR, Krueger AS, Molnar RA, Ledell JT, Heilbut AM, Short GF III, Giusti LC, Nolan GP, Magid OA, Lee MS, Borisy AA, Stockwell BR, Keith CT (2007) Chemical combination effects predict connectivity in biological systems. Mol Syst Biol 3:80
63. Avis I, Martinez A, Tauler J, Zudaire E, Mayburd A, Abu-Ghazaleh R, Ondrey F, Mulshine JL (2005) Inhibitors of the arachidonic acid pathway and peroxisome proliferator- activated receptor ligands have superadditive effects on lung cancer growth inhibition. Cancer Res 65:4181-4190
64. Liby KT, Yore MM, Sporn MB (2007) Triterpenoids and rexinoids as multifunctional agents for the prevention and treatment of cancer. Nat Rev Cancer 7:357-369
65. Grosser T, Fries S, FitzGerald GA (2006) Biological basis for the cardiovascular consequences of COX-2 inhibition: therapeutic challenges and opportunities. J Clin Invest 116:4-15
66. Frantz S (2005) Drug discovery: playing dirty. Nature 437:942-943
67. Millan MJ (2006) Multi-target strategies for the improved treatment of depressive states: conceptual foundations and neuronal substrates, drug discovery and therapeutic application. Pharmacol Ther 110:135-370
68. Farah A (2005) Atypicality of atypical antipsychotics. Prim Care Companion J Clin Psychiatry 7:268-274
69. Roth BL, Sheffler DJ, Kroeze WK (2004) Magic shotguns versus magic bullets: selectively non-selective drugs for mood disorders and schizophrenia. Nat Rev Drug Discov 3:353-359
70. Stahl SM (1998) What makes an antipsychotic atypical? J Clin Psychiatry 59:403-404
71. Ahmad N, Feyes DK, Nieminen AL, Agarwal R, Mukhtar H (1997) Green tea constituent epigallocatechin-3-gallate and induction of apoptosis and cell cycle arrest in human carcinoma cells. J Natl Cancer Inst 89: 1881-1886
72. Khan N, Afaq F, Saleem M, Ahmad N, Mukhtar H (2006) Targeting multiple signaling pathways by green tea polyphenol (?)-epigallocatechin-3-gallate. Cancer Res 66:2500-2505
73. Khan N, Afaq F, Mukhtar H (2007) Apoptosis by dietary factors: the suicide solution for delaying cancer growth. Carcinogenesis 28:233-239
74. Hopkins AL (2008) Network pharmacology: the next paradigm in drug discovery. Nat Chem Biol 4:682-690
75. Dessalew N, Workalemahu M (2008) On the paradigm shift towards multitarget selective drug design. Curr Comput Aided Drug Des 4:76-90
76. Korcsmaros T, Szalay MS, Bode C, Kovacs IA, Csermely P (2007) How to design multitarget drugs: target search options in cellular networks. Expert Opin Drug Discov 2:1-10
77. Barabasi AL, Albert R (1999) Emergence of scaling in random networks. Science 286:509-512
78. Palla G, Derenyi I, Farkas I, Vicsek T (2005) Uncovering the overlapping community structure of complex networks in nature and society. Nature 435:814-818
79. Nacher JC, Schwartz JM (2008) A global view of drug-therapy interactions. BMC Pharmacol 8:5
80. Csermely P, Agoston V, Pongor S (2005) The efficiency of multi-target drugs: the network approach might help drug design. Trends Pharmacol Sci 26:178-182
81. Strong M, Eisenberg D (2007) The protein network as a tool for finding novel drug targets. Prog Drug Res 64:191, 193-215
82. Morphy R, Rankovic Z (2007) Fragments, network biology and designing multiple ligands. Drug Discov Today 12:156-160
83. Hyduke DR, Jarboe LR, Tran LM, Chou KJ, Liao JC (2007) Integrated network analysis identifies nitric oxide response networks and dihydroxyacid dehydratase as a crucial target in Escherichia coli. Proc Natl Acad Sci USA 104:8484-8489
84. Schrattenholz A, Groebe K (2007) What does it need to be a biomarker? Relationships between resolution, differential quantification and statistical validation of protein surrogate biomarkers. Electrophoresis 28:1970-1979
85. Kovacs IA, Szalay MS, Csermely P (2005) Water and molecular chaperones act as weak links of protein folding networks: energy landscape and punctuated equilibrium changes point towards a game theory of proteins. FEBS Lett 579:2254-2260
86. Shen-Orr SS, Milo R, Mangan S, Alon U (2002) Network motifs in the transcriptional regulation network of Escherichia coli. Nat Genet 31:64-68
87. Jiang R, Tu Z, Chen T, Sun F (2006) Network motif identification in stochastic networks. Proc Natl Acad Sci USA 103:9404-9409
88. Milo R, Shen-Orr S, Itzkovitz S, Kashtan N, Chklovskii D, Alon U (2002) Network motifs: simple building blocks of complex networks. Science 298:824-827
89. Milo R, Itzkovitz S, Kashtan N, Levitt R, Shen-Orr S, Ayzenshtat I, Sheffer M, Alon U (2004) Superfamilies of evolved and designed networks. Science 303:1538-1542
90. Agoston V, Csermely P, Pongor S (2005) Multiple weak hits confuse complex systems: a transcriptional regulatory network as an example. Phys Rev E Stat Nonlin Soft Matter Phys 71:051909
91. Sivachenko AY, Yuryev A (2007) Pathway analysis software as a tool for drug target selection, prioritization and validation of drug mechanism. Expert Opin Ther Targets 11:411-421
92. Herwig R, Lehrach H (2006) Expression profiling of drug response - from genes to pathways. Dialogues Clin Neurosci 8:283-293
93. Elrick MM, Walgren JL, Mitchell MD, Thompson DC (2006) Proteomics: recent applications and new technologies. Basic Clin Pharmacol Toxicol 98:432-441
94. Schrattenholz A, Klemm M (2006) How human embryonic stem cell research can impact in vitro drug screening technologies of the future. In: Marx U, Sandig V (eds) Drug testing in vitro: breakthroughs and trends in cell culture technology. Wiley/VCH, New York, pp 205-228
95. Schrattenholz A, Klemm M (2007) Neuronal cell culture from human embryonic stem cells as in vitro model for neuroprotection. ALTEX 24:9-15
96. Malmstrom J, Lee H, Aebersold R (2007) Advances in proteomic workflows for systems biology. Curr Opin Biotechnol 18:378-384
97. Hunzinger C, Schrattenholz A, Poznanovic S, Schwall GP, Stegmann W (2006) Comparison of different separation technologies for proteome analyses: isoform resolution as a prerequisite for the definition of protein biomarkers on the level of posttranslational modifications. J Chromatogr A 1123:170-181
98. Ho E, Webber R, Wilkins MR (2007) Interactive three-dimensional visualization and contextual analysis of protein interaction networks. J Proteome Res 7:104-112
99. Grillari J, Katinger H, Voglauer R (2006) Aging and the ubiquitinome: traditional and non-traditional functions of ubiquitin in aging cells and tissues. Exp Gerontol 41:1067-1079
100. Tanaka K (2009) The proteasome: overview of structure and functions. Proc Jpn Acad B Phys Biol Sci 85:12-36
101. Ulrich HD (2009) The SUMO system: an overview. Methods Mol Biol 497:3-16
102. Schrattenholz A, Šoškic V, Groebe K (2010) Synchronisation of posttranslational modifications during ageing: time is a crucial biological dimension. Ann NY Acad Sci 1197:118-128
103. Brazma A, Hingamp P, Quackenbush J, Sherlock G, Spellman P, Stoeckert C, Aach J, Ansorge W, Ball CA, Causton HC, Gaasterland T, Glenisson P, Holstege FC, Kim IF, Markowitz V, Matese JC, Parkinson H, Robinson A, Sarkans U, Schulze-Kremer S, Stewart J, Taylor R, Vilo J, Vingron M (2001) Minimum information about a microarray experiment (MIAME)-toward standards for microarray data. Nat Genet 29:365-371
104. Taylor CF, Field D, Sansone SA, Aerts J, Apweiler R, Ashburner M, Ball CA, Binz PA, Bogue M, Booth T, Brazma A, Brinkman RR, Michael CA, Deutsch EW, Fiehn O, Fostel J, Ghazal P, Gibson F, Gray T, Grimes G, Hancock JM, Hardy NW, Hermjakob H, Julian RK Jr, Kane M, Kettner C, Kinsinger C, Kolker E, Kuiper M, Le NN, Leebens- Mack J, Lewis SE, Lord P, Mallon AM, Marthandan N, Masuya H, McNally R, Mehrle A, Morrison N, Orchard S, Quackenbush J, Reecy JM, Robertson DG, Rocca-Serra P, Rodriguez H, Rosenfelder H, Santoyo-Lopez J, Scheuermann RH, Schober D, Smith B, Snape J, Stoeckert CJ Jr, Tipton K, Sterk P, Untergasser A, Vandesompele J, Wiemann S (2008) Promoting coherent minimum reporting guidelines for biological and biomedical investigations: the MIBBI project. Nat Biotechnol 26:889-896
105. Taylor CF, Paton NW, Lilley KS, Binz PA, Julian RK Jr, Jones AR, Zhu W, Apweiler R, Aebersold R, Deutsch EW, Dunn MJ, Heck AJ, Leitner A, Macht M, Mann M, Martens L, Neubert TA, Patterson SD, Ping P, Seymour SL, Souda P, Tsugita A, Vandekerckhove J, Vondriska TM, Whitelegge JP, Wilkins MR, Xenarios I, Yates JR III, Hermjakob H (2007) The minimum information about a proteomics experiment (MIAPE). Nat Biotechnol 25:887-893
106. Jones AR, Miller M, Aebersold R, Apweiler R, Ball CA, Brazma A, Degreef J, Hardy N, Hermjakob H, Hubbard SJ, Hussey P, Igra M, Jenkins H, Julian RK Jr, Laursen K, Oliver SG, Paton NW, Sansone SA, Sarkans U, Stoeckert CJ Jr, Taylor CF, Whetzel PL, White JA, Spellman P, Pizarro A (2007) The Functional Genomics Experiment model (FuGE): an extensible framework for standards in functional genomics. Nat Biotechnol 25:1127-1133
107. Kaiser J (2002) Proteomics. Public-private group maps out initiatives. Science 296:827
108. Orchard S, Hermjakob H, Apweiler R (2003) The proteomics standards initiative. Proteomics 3:1374-1376
109. Jones P, Cote RG, Martens L, Quinn AF, Taylor CF, Derache W, Hermjakob H, Apweiler R (2006) PRIDE: a public repository of protein and peptide identifications for the proteomics community. Nucleic Acids Res 34:D659-D663
110. Kanehisa M, Goto S, Kawashima S, Okuno Y, Hattori M (2004) The KEGG resource for deciphering the genome. Nucleic Acids Res 32:D277-D280
111. Junker BH, Klukas C, Schreiber F (2006) VANTED: a system for advanced data analysis and visualization in the context of biological networks. BMC Bioinform 7:109
112. Schomburg I, Chang A, Schomburg D (2002) BRENDA, enzyme data and metabolic information. Nucleic Acids Res 30:47-49
113. Sauro HM, Hucka M, Finney A, Wellock C, Bolouri H, Doyle J, Kitano H (2003) Next generation simulation tools: the Systems Biology Workbench and BioSPICE integration. OMICS 7:355-372
114. Hucka M, Finney A, Sauro HM, Bolouri H, Doyle JC, Kitano H, Arkin AP, Bornstein BJ, Bray D, Cornish-Bowden A, Cuellar AA, Dronov S, Gilles ED, Ginkel M, Gor V, Goryanin II, Hedley WJ, Hodgman TC, Hofmeyr JH, Hunter PJ, Juty NS, Kasberger JL, Kremling A, Kummer U, Le NN, Loew LM, Lucio D, Mendes P, Minch E, Mjolsness ED, Nakayama Y, Nelson MR, Nielsen PF, Sakurada T, Schaff JC, Shapiro BE, Shimizu TS, Spence HD, Stelling J, Takahashi K, Tomita M, Wagner J, Wang J (2003) The systems biology markup language (SBML): a medium for representation and exchange of biochemical network models. Bioinformatics 19:524-531
115. Borger S, Liebermeister W, Klipp E (2006) Prediction of enzyme kinetic parameters based on statistical learning. Genome Inform 17:80-87
116. Simon GM, Cravatt BF (2008) Challenges for the 'chemical-systems' biologist. Nat Chem Biol 4:639-642
117. Salisbury CM, Cravatt BF (2008) Optimization of activity-based probes for proteomic profiling of histone deacetylase complexes. J Am Chem Soc 130:2184-2194
118. Rexach JE, Clark PM, Hsieh-Wilson LC (2008) Chemical approaches to understanding O-GlcNAc glycosylation in the brain. Nat Chem Biol 4:97-106
119. Martin BR, Cravatt BF (2009) Large-scale profiling of protein palmitoylation in mammalian cells. Nat Methods 6:135-138
120. Codelli JA, Baskin JM, Agard NJ, Bertozzi CR (2008) Second-generation difluorinated cyclooctynes for copper-free click chemistry. J Am Chem Soc 130:11486-11493
121. Ovaa H, van Swieten PF, Kessler BM, Leeuwenburgh MA, Fiebiger E, van den Nieuwendijk AM, Galardy PJ, van der Marel GA, Ploegh HL, Overkleeft HS (2003) Chemistry in living cells: detection of active proteasomes by a two-step labeling strategy. Angew Chem Int Ed Engl 42:3626-3629
122. Jorgensen JT (2009) New era of personalized medicine: a 10-year anniversary. Oncologist 14:557-558
123. Kurpiers T, Mootz HD (2009) Bioorthogonal ligation in the spotlight. Angew Chem Int Ed Engl 48:1729-1731